Welcome to LookChem.com Sign In|Join Free

CAS

  • or

73-03-0

Post Buying Request

73-03-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

73-03-0 Usage

Plant extracts

In 1951, German scientist Cunningham had purified a crystal from the Cordyceps militaris and named it cordycepin. From then on, the crordycepin reported in published literature abroad regarding to its antitumor, antiviral efficacy as well as extraction and purification had been all obtained from Cordyceps instead of being from Cordyceps sinensis which contains only trace amount of Cordycepin. Cordyceps is the major active ingredient contained in Cordyceps (especially nucleoside). It belongs to a kind of nucleoside drugs, purine alkaloids and is also the first kind of nuclear glycosides antibiotics isolated from fungus. Owing to its special efficacy in repairing cells and protection of the genetic code of life, it has become one of the leaders in modern biomedicine. Cordycepin is a drug of natural source with various kinds of pharmacological effects such as anti-tumor, antibacterial and antiviral, immunomodulatory as well as free radical-scavenging, etc., and has good prospects for clinical application. At present time, the research on cordycepin present study is becoming an extremely active area in the field of pharmaceutical chemistry. As a structural analogue of adenosine, cordycepin can inhibit Bacillus subtilis, Mycobacterium tuberculosis of birds and Ehrlich ascites tumor cells with inhibitory effect on the RNA and DNA synthesis inhibition of cancer cells, therefore having very strong inhibitory effect on the human nose and pharynx cancer (KD) cells. The clinically applied cordycepin is mostly used for adjuvant treatment of malignant tumors with the cases of improved clinical symptoms accounting for more than 91.7%; it is mainly used for the treatment of patients of nasal cancer, throat cancer, lung cancer, leukemia, brain cancer and other malignant tumor. Cordycepin is extracted from the Cordyceps and is the mostly nutritious active substance inside Cordyceps. Its major composition is Cordyceps polysaccharide, Cordyceps acid as well as Cordyceps SOD and is a kind of natural nutrients of high health function. It can activate dormant cells, repair diseased cells, propagate the new living cells, clean up dead cells and is of great value in improving immunity, anti-fatigue as well as improving the body's energy.

Pharmacological effects

Most currently known Cordyceps fungus contains Cordycepin, which obviously plays an important role in the anti-tumor effect. Jagger believes the cordycepin contained in Cordyceps fungus can inhibit tumorigenesis through three possible mechanisms: 1. The free alcoholic group contained in cordycepin can be incorporated into the DNA of cancer cells and takes effect. 2. Cordycepin can inhibit the phosphorylation of nucleoside or nucleotide to generate the derivatives of diphosphate and triphosphate, thereby inhibiting the synthesis of nucleic acids in tumor cell. 3. Cordycepin can block the amination of xanthylic acid into guanylate. In 1977, Müller et al found that cordycepin had strong inhibitory effect against the proliferation of L5718Y cell with the ED50 being 0.27μg; this inhibitory effect can be eliminated by adenosine but not 2'-deoxy-nucleosides; The tritium marked Cordyceps trial have showed that cordycepin can be incorporated into RNA rather than DNA. The cordycepin, inside the cell, can be phosphorylated to 3'-ATP; 3'-ATP has no effect on the activity of the DNA-dependent DNA polymerase α and β in L5718Y cells, but has strong inhibitory effect on the nuclear Poly (a) polysaccharide which will inevitably lead to a maturation defect of mRNA, further negatively affecting the formation of mRNA and protein synthesis. The anti-tumor effects of Cordyceps may be related to this mechanism. In 1997, the United States has applied cordycepin to third-period clinical trials for the treatment of pre-B and pre-T acute lymphocytic leukemia, while cordycepin also exhibit strong anti-fungal, anti-HIV viral and selective inhibition activity on the activity of Clostridium genus. In 1985, with in vitro experiments, Jiang ping et al observed the cytotoxicity of Cordyceps sinensis and cultured mycelium (Qinghai) on ECA cells. For the treatment of in vitro cell culture ECA, the result showed that when they two were at the lowest effective concentration 0.405mg/ml and 25mg/ml, the total infection rate was 100%, 80%, respectively, indicating that the drug has different strengths of ECA cytotoxicity. Comprehensive in vivo tests speculated that the anti-tumor effect is correlated with the certain amount of 3'-deoxy-nucleosides contained in the drug and Cordyceps polysaccharides as well as the relative balance between the overall immune regulatory function of the drugs and its effect of maintaining body immunity. Cordyceps sinensis has certain cytotoxic effect, which is consistent with the report regarding to the strong cytotoxicity of cordycepin-resistant L1210. The above information is edited by the lookchem of Dai Xiongfeng.

Uses

Different sources of media describe the Uses of 73-03-0 differently. You can refer to the following data:
1. Cordycepin is known to have various kinds of effects of improving immune skill, anti-aging, anti-fatigue, anti-cancer, anti-bacterial, anti-virus, lowering blood glucose and lipid and male hormone.
2. First reported nucleoside antibiotic.

Description

Cordycepin (73-03-0) is an adenosine analog lacking the hydroxyl at the 3’ position. Inhibits PARP1?and polyadenylation2. Displays anti-inflammatory effects1,3?and neuroprotective effects by inhibiting Aβ-induced apoptosis in hippocampal neurons4. Induces apoptosis in a variety of cancer cell lines5. Displays antiobesity effects.6?Inhibits cell senescence via activation of AMPK.7?Maintains stem cell pluripotency and increases iPS cell generation efficiency.8

Chemical Properties

Crystalline Solid

Biological Activity

Nucleoside analog that acts as an anticancer and antifungal agent. Can be converted to 3'-deoxyadenosine triphosphate (3'-dATP), which inhibits ATP-dependent DNA synthesis. Inhibits growth of various tumor cells in vitro .

Biochem/physiol Actions

Cordycepin is an adenosine analogue that is readily converted to cordycepin 5′-triphosphate; can be used for 3′-end labeling of RNA.

Purification Methods

3'-Deoxyadenosine forms needles from EtOH, n-BuOH and n-PrOH, and a monohydrate from H2O. It has max 260nm ( 14,600) in EtOH. The picrate has m 195o(dec, yellow crystals from H2O). [Kaczka et al. Biochim Biophys Acta 14 456 1964, Todd & Ulbricht J Chem Soc 3275 1960, Lee et al. J Am Chem Soc 83 1906 1961, Walton et al. J Am Chem Soc 86 2952 1964, Beilstein 26 III/IV 3594.]

References

1) Kim?et al. (2011),?Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP; Mol. Med.?17?893 2) Kondrashov?et al.?(2012),?Inhibition of polyadenylation reduces inflammatory gene induction; RNA?18?2236 3)Yang?et al.?(2017),?Cordycepin inhibits LPS-induced inflammatory response by modulating NOD-Like Receptor Protein 3 inflammasome activation; Biomed. Pharmacother.?95?1777 4) Song?et al.?(2018),?Neuroprotective effects of cordycepin inhibit Aβ-induced apoptosis in hippocampal neurons; Neurotoxicology?68?73 5) Zhang?et al.?(2018),?Cordycepin induces apoptosis in human pancreatic cancer cells via the mitochondrial-mediated intrinsic pathway and suppresses tumor growth in vivo; OncoTargets Ther.?11?4479 6) Li?et al.?(2018),?Cordycepin modulates body weight by reducing prolactin via an adenosine A1 receptor; Curr. Pharm. Des.,?24?3240 7) Wang?et al?(2019)?Cordycepin prevents radiation ulcer by inhibiting cell senescence via NRF2 and SMPK in rodents;?Nat. Commun.?10?2538 8) Wang?et al.?(2020)?The novel application of cordycepin in maintaining stem cell pluripotency and increasing iPS cell generation efficiency; Sci. Rep.?10?2187

Check Digit Verification of cas no

The CAS Registry Mumber 73-03-0 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 7 and 3 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 73-03:
(4*7)+(3*3)+(2*0)+(1*3)=40
40 % 10 = 0
So 73-03-0 is a valid CAS Registry Number.

73-03-0 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (C2689)  Cordycepin from Cordyceps militaris  >98.0%(HPLC)

  • 73-03-0

  • 25mg

  • 890.00CNY

  • Detail
  • TCI America

  • (C2815)  Cordycepin Hydrate  >98.0%(HPLC)

  • 73-03-0

  • 25mg

  • 980.00CNY

  • Detail

73-03-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name Cordycepin

1.2 Other means of identification

Product number -
Other names (-)-cordycepin

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:73-03-0 SDS

73-03-0Synthetic route

5'-O-(o-toluoyl)-2'-O-acetyl-3'-deoxy-6-chloropurine

5'-O-(o-toluoyl)-2'-O-acetyl-3'-deoxy-6-chloropurine

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
With ammonia In methanol; ethanol at -20℃; for 48h;100%
9-(2,3-anhydro-β-D-ribofuranosyl)adenine
2627-64-7

9-(2,3-anhydro-β-D-ribofuranosyl)adenine

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
With lithium triethylborohydride In tetrahydrofuran; dimethyl sulfoxide 1.) 4 deg C, 1 h, 2.) 19-22 deg C, overnight;98%
With lithium triethylborohydride In dimethyl sulfoxide53%
With lithium triethylborohydride; acetic acid 1.) Me2SO, THF, 1 h ice-water cooling, then -> room temperature, 2.) H2O; Yield given. Multistep reaction;
9-((2R,3R,5S)-3-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-9H-purin-6-amine
116285-72-4

9-((2R,3R,5S)-3-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-9H-purin-6-amine

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
With tetrabutyl ammonium fluoride In tetrahydrofuran at 20℃;98%
C14H16ClN5O5

C14H16ClN5O5

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
With palladium on activated charcoal; hydrogen In methanol at 25℃; under 37503.8 Torr; for 8h;95%
N6,2',5'-tribenzoyl-3'-deoxyadenosine
4395-38-4

N6,2',5'-tribenzoyl-3'-deoxyadenosine

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
With sodium methylate In methanol for 1h; Heating;94%
((2S,4R,5R)-4-acetoxy-5-(6-amino-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl acetate
71196-28-6

((2S,4R,5R)-4-acetoxy-5-(6-amino-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl acetate

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
With ammonia In methanol for 3h; Ambient temperature;93%
With potassium carbonate In methanol; water at 20℃; for 3h;93%
With methanol; ammonia at 0 - 60℃; for 16h;90%
Stage #1: ((2S,4R,5R)-4-acetoxy-5-(6-amino-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl acetate With sodium hydroxide In methanol at 25℃; for 1h;
Stage #2: With ammonium chloride In methanol for 0.5h; Reagent/catalyst;
87%
6-N-5'-O-Bis-<4-methoxytriphenylmethyl>-3'-deoxyadenosine
101857-01-6

6-N-5'-O-Bis-<4-methoxytriphenylmethyl>-3'-deoxyadenosine

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
With acetic acid at 20℃; for 12h;92%
(2R,3R,5S)-2-(6-amino-purin-9-yl)-5-(tert-butyl-dimethyl-silanyloxymethyl)tetrahydrofuran-3-ol
117068-51-6

(2R,3R,5S)-2-(6-amino-purin-9-yl)-5-(tert-butyl-dimethyl-silanyloxymethyl)tetrahydrofuran-3-ol

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
With tetrabutyl ammonium fluoride In tetrahydrofuran at 25℃; for 0.5h;91%
9-(3-deoxy-5-O-trityl-β-D-erythro-pentofuranosyl)adenine
90813-62-0

9-(3-deoxy-5-O-trityl-β-D-erythro-pentofuranosyl)adenine

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
With acetic acid In methanol; dichloromethane at 20℃; for 4h; pH=Ca. 4;90%
9-<5-O-(monomethoxytrityl)-3-deoxy-β-D-erythro-pentofuranosyl>adenine
51763-58-7

9-<5-O-(monomethoxytrityl)-3-deoxy-β-D-erythro-pentofuranosyl>adenine

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
With acetic acid at 20℃; for 2h;85%
9-(3'-Deoxy-3'-iodo-β-D-xylofuranosyl)adenine
54937-38-1

9-(3'-Deoxy-3'-iodo-β-D-xylofuranosyl)adenine

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
With 5% palladium on barium sulphate; hydrogen; triethylamine In methanol under 2280.15 Torr;80%
2',3'-dehydroadenosine
2627-64-7, 4336-89-4, 40110-98-3

2',3'-dehydroadenosine

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
With lithium triethylborohydride In tetrahydrofuran; dimethyl sulfoxide at 4 - 20℃; for 17h; Inert atmosphere;77%
6-heptanoylamido-9-(3-deoxy-2,5-di-O-benzoyl-β-D-erythropentofuranosyl)-purine

6-heptanoylamido-9-(3-deoxy-2,5-di-O-benzoyl-β-D-erythropentofuranosyl)-purine

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
75%
C14H16BrN5O5

C14H16BrN5O5

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
With formic acid; palladium 10% on activated carbon In methanol at 40℃; for 24h;75%
3'-bromo-3'-deoxy-adenosine hydrochloride

3'-bromo-3'-deoxy-adenosine hydrochloride

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
With 5%-palladium/activated carbon; hydrogen; sodium acetate In ethanol; water at 25℃; under 1551.49 Torr; for 44h; Inert atmosphere;52.5%
Stage #1: 3'-bromo-3'-deoxy-adenosine hydrochloride With sodium acetate In ethanol; water for 1h;
Stage #2: With hydrogen In ethanol; water at 20℃; under 760.051 - 1520.1 Torr; for 36h; Reagent/catalyst; Solvent;
100 g
2,2-Dimethyl-propionic acid 4-acetoxy-5-(6-benzoylamino-purin-9-yl)-tetrahydro-furan-2-ylmethyl ester

2,2-Dimethyl-propionic acid 4-acetoxy-5-(6-benzoylamino-purin-9-yl)-tetrahydro-furan-2-ylmethyl ester

A

cordycepin
73-03-0

cordycepin

B

cordycepin

cordycepin

Conditions
ConditionsYield
With sodium methylate In methanolA 42%
B n/a
2,2-Dimethyl-propionic acid (2S,4R,5R)-4-acetoxy-5-(6-benzoylamino-purin-9-yl)-tetrahydro-furan-2-ylmethyl ester
162825-78-7

2,2-Dimethyl-propionic acid (2S,4R,5R)-4-acetoxy-5-(6-benzoylamino-purin-9-yl)-tetrahydro-furan-2-ylmethyl ester

A

cordycepin
73-03-0

cordycepin

B

N-(9-((2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide
76902-49-3

N-(9-((2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide

Conditions
ConditionsYield
With sodium methylate In methanol at 20℃; for 20h;A 42%
B 16%
2',5'-di-O-acetyl-3'-deoxy-N6-<2-(4-nitrophenyl)ethoxycarbonyl>adenosine
161001-78-1

2',5'-di-O-acetyl-3'-deoxy-N6-<2-(4-nitrophenyl)ethoxycarbonyl>adenosine

A

cordycepin
73-03-0

cordycepin

B

N6-carbamoyl-3'-deoxyadenosine

N6-carbamoyl-3'-deoxyadenosine

Conditions
ConditionsYield
With ammonia for 18h; Ambient temperature;A 25%
B 41%
2',3'-di-O-p-tolylsulphonyl-9-β-D-xylofuranosyladenine
127246-65-5

2',3'-di-O-p-tolylsulphonyl-9-β-D-xylofuranosyladenine

A

3'-deoxydenosine
6998-75-0

3'-deoxydenosine

B

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
With lithium triethylborohydride In tetrahydrofuran for 16h; Ambient temperature;A 10%
B 36%
N-acetyl-2',5'-O-diacetyl-3'-iodo-3'-deoxyadenosine

N-acetyl-2',5'-O-diacetyl-3'-iodo-3'-deoxyadenosine

A

cordycepin
73-03-0

cordycepin

B

2',3'-Dideoxyadenosine
4097-22-7

2',3'-Dideoxyadenosine

Conditions
ConditionsYield
Stage #1: N-acetyl-2',5'-O-diacetyl-3'-iodo-3'-deoxyadenosine With lithium aluminium tetrahydride; 2,2'-azobis(isobutyronitrile) In tetrahydrofuran; toluene for 12h; Reflux;
Stage #2: With sodium methylate In methanol at 60℃; for 6h; Reagent/catalyst; Solvent;
A 31.3%
B 4.8%
N-acetyl-2',5'-O-diacetyl-3'-iodo-3'-deoxyadenosine

N-acetyl-2',5'-O-diacetyl-3'-iodo-3'-deoxyadenosine

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
Stage #1: N-acetyl-2',5'-O-diacetyl-3'-iodo-3'-deoxyadenosine With lithium aluminium tetrahydride; 2,2'-azobis(isobutyronitrile) In tetrahydrofuran; toluene for 4h; Reflux;
Stage #2: With sodium methylate In methanol at 60℃; for 6h; Reagent/catalyst; Solvent;
30.2%
9-(5-O-acetyl-3-deoxy-β-D-erythro-pentofuranosyl)adenine
137530-37-1

9-(5-O-acetyl-3-deoxy-β-D-erythro-pentofuranosyl)adenine

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
With potassium hydroxide In acetone for 1h;4 mg
3'-deoxy-N6-<2-(4-nitrophenyl)ethoxycarbonyl>adenosine
112237-60-2

3'-deoxy-N6-<2-(4-nitrophenyl)ethoxycarbonyl>adenosine

A

cordycepin
73-03-0

cordycepin

B

N6-carbamoyl-3'-deoxyadenosine

N6-carbamoyl-3'-deoxyadenosine

Conditions
ConditionsYield
With ammonia Ambient temperature;
Benzoic acid (2S,4R,5R)-4-acetoxy-5-(6-benzoylamino-purin-9-yl)-tetrahydro-furan-2-ylmethyl ester
157025-63-3

Benzoic acid (2S,4R,5R)-4-acetoxy-5-(6-benzoylamino-purin-9-yl)-tetrahydro-furan-2-ylmethyl ester

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
With MeOT; ammonia Ambient temperature; Yield given;
2',5'-di-O-acetyl-3'-deoxy-N6-<2-(4-nitrophenyl)ethoxycarbonyl>adenosine
161001-78-1

2',5'-di-O-acetyl-3'-deoxy-N6-<2-(4-nitrophenyl)ethoxycarbonyl>adenosine

A

2-(4-nitrophenyl)ethanol
100-27-6

2-(4-nitrophenyl)ethanol

B

cordycepin
73-03-0

cordycepin

C

2-(4-nitrophenyl)ethyl carbamate

2-(4-nitrophenyl)ethyl carbamate

D

N6-carbamoyl-3'-deoxyadenosine

N6-carbamoyl-3'-deoxyadenosine

Conditions
ConditionsYield
With ammonia for 18h; Product distribution; Mechanism; Ambient temperature;
9-(2'-O-Acetyl-3'-bromo-3'-deoxy-β-D-xylofuranosyl)adenine
42867-78-7

9-(2'-O-Acetyl-3'-bromo-3'-deoxy-β-D-xylofuranosyl)adenine

A

cordycepin
73-03-0

cordycepin

B

2',3'-Dideoxyadenosine
4097-22-7

2',3'-Dideoxyadenosine

Conditions
ConditionsYield
With sodium hydroxide; sodium acetate; palladium on activated charcoal 1.) CH3CN, RT, 6 h; Yield given. Multistep reaction. Yields of byproduct given;
9-(2-O-acetyl-3-bromo-3-deoxy-5-O-(2,4,4-trimethyl-5-oxo-1,3-dioxolan-2-yl)-β-D-xylofuranosyl)adenine
37731-72-9

9-(2-O-acetyl-3-bromo-3-deoxy-5-O-(2,4,4-trimethyl-5-oxo-1,3-dioxolan-2-yl)-β-D-xylofuranosyl)adenine

A

cordycepin
73-03-0

cordycepin

B

2',3'-Dideoxyadenosine
4097-22-7

2',3'-Dideoxyadenosine

Conditions
ConditionsYield
With sodium hydroxide; sodium acetate; palladium on activated charcoal 1.) CH3CN, RT, 3 h; Yield given. Multistep reaction. Yields of byproduct given;
9-(5-O-acetyl-3-bromo-3-deoxy-β-D-xylofuranosyl)adenine
134665-27-3

9-(5-O-acetyl-3-bromo-3-deoxy-β-D-xylofuranosyl)adenine

cordycepin
73-03-0

cordycepin

Conditions
ConditionsYield
With sodium hydroxide; sodium carbonate; palladium on activated charcoal 1.) aq. CH3CN, RT, 24 h; Yield given. Multistep reaction;
Acetic acid (2R,3S,4S,5R)-5-(6-amino-purin-9-yl)-3-bromo-4-methanesulfonyloxy-tetrahydro-furan-2-ylmethyl ester

Acetic acid (2R,3S,4S,5R)-5-(6-amino-purin-9-yl)-3-bromo-4-methanesulfonyloxy-tetrahydro-furan-2-ylmethyl ester

A

cordycepin
73-03-0

cordycepin

B

2',3'-Dideoxyadenosine
4097-22-7

2',3'-Dideoxyadenosine

Conditions
ConditionsYield
With sodium hydroxide; sodium carbonate; palladium on activated charcoal 1.) aq. CH3CN, RT, 2 h; Yield given. Multistep reaction. Yields of byproduct given;
Pentanoic acid (2R,3S,4S,5R)-5-acetoxymethyl-2-(6-amino-purin-9-yl)-4-bromo-tetrahydro-furan-3-yl ester

Pentanoic acid (2R,3S,4S,5R)-5-acetoxymethyl-2-(6-amino-purin-9-yl)-4-bromo-tetrahydro-furan-3-yl ester

A

cordycepin
73-03-0

cordycepin

B

2',3'-Dideoxyadenosine
4097-22-7

2',3'-Dideoxyadenosine

Conditions
ConditionsYield
With sodium hydroxide; sodium acetate; palladium on activated charcoal 1.) CH3CN, RT, 11 h; Yield given. Multistep reaction. Yields of byproduct given;
cordycepin
73-03-0

cordycepin

acetic anhydride
108-24-7

acetic anhydride

((2S,4R,5R)-4-acetoxy-5-(6-amino-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl acetate
71196-28-6

((2S,4R,5R)-4-acetoxy-5-(6-amino-9H-purin-9-yl)tetrahydrofuran-2-yl)methyl acetate

Conditions
ConditionsYield
With pyridine; dmap for 4h; Ambient temperature;100%
With pyridine at 20℃; for 0.5h;82%
cordycepin
73-03-0

cordycepin

ortho-toluoyl chloride
933-88-0

ortho-toluoyl chloride

3',5'-bis-O-o-toluoyl-6-N-O-o-toluoyl-3'-deoxyadenosine

3',5'-bis-O-o-toluoyl-6-N-O-o-toluoyl-3'-deoxyadenosine

Conditions
ConditionsYield
With pyridine In N,N-dimethyl-formamide at 0 - 20℃; Inert atmosphere;99%
cordycepin
73-03-0

cordycepin

3’-deoxyinosine
13146-72-0

3’-deoxyinosine

Conditions
ConditionsYield
With Azodicarboxamid In water at 50℃; for 1h; Deamination;95%
With water at 37℃; for 1h; Enzymatic reaction;
cordycepin
73-03-0

cordycepin

tert-butylchlorodiphenylsilane
58479-61-1

tert-butylchlorodiphenylsilane

3'-deoxy-5'-O-[(tertbutyl)diphenylsilyl]adenosine
862179-59-7

3'-deoxy-5'-O-[(tertbutyl)diphenylsilyl]adenosine

Conditions
ConditionsYield
With 1H-imidazole In N,N-dimethyl-formamide at 20℃; for 4h; Cooling;92%
With 1H-imidazole In N,N-dimethyl-formamide at 20℃;90%
With pyridine at 40℃; for 6h;85%
cordycepin
73-03-0

cordycepin

trityl chloride
76-83-5

trityl chloride

9-(3-deoxy-5-O-trityl-β-D-erythro-pentofuranosyl)adenine
90813-62-0

9-(3-deoxy-5-O-trityl-β-D-erythro-pentofuranosyl)adenine

Conditions
ConditionsYield
With pyridine at 50℃;88%
In pyridine for 120h; Ambient temperature;66%
cordycepin
73-03-0

cordycepin

benzoyl chloride
98-88-4

benzoyl chloride

N6,2',5'-tribenzoyl-3'-deoxyadenosine
4395-38-4

N6,2',5'-tribenzoyl-3'-deoxyadenosine

Conditions
ConditionsYield
With pyridine at 0℃; for 2.5h;88%
cordycepin
73-03-0

cordycepin

benzoyl chloride
98-88-4

benzoyl chloride

(2R,3R,5S)-2-[6-(N-benzoylbenzamido)-9H-purin-9-yl]-5-[(benzoyloxy)methyl]oxolan-3-yl benzoate
66884-45-5

(2R,3R,5S)-2-[6-(N-benzoylbenzamido)-9H-purin-9-yl]-5-[(benzoyloxy)methyl]oxolan-3-yl benzoate

Conditions
ConditionsYield
With pyridine at 80℃; for 4h;88%
In pyridine for 2h; Ambient temperature;86%
With pyridine at 125℃; for 3h;47%
In pyridine
With pyridine at 65℃; for 4h; Heating / reflux;
cordycepin
73-03-0

cordycepin

tert-butyldimethylsilyl chloride
18162-48-6

tert-butyldimethylsilyl chloride

9-((2R,3R,5S)-3-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-9H-purin-6-amine
116285-72-4

9-((2R,3R,5S)-3-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)tetrahydrofuran-2-yl)-9H-purin-6-amine

Conditions
ConditionsYield
With 1H-imidazole; dmap In N,N-dimethyl-formamide at 0 - 23℃; for 10h; Inert atmosphere;86%
With 1H-imidazole In N,N-dimethyl-formamide at 20℃;41%
With 1H-imidazole; dmap In N,N-dimethyl-formamide for 0.5h;
With 1H-imidazole; dmap In N,N-dimethyl-formamide for 0.5h;
With 1H-imidazole In N,N-dimethyl-formamide at 20℃; for 16h;1.56 g
vinyl acetate
108-05-4

vinyl acetate

cordycepin
73-03-0

cordycepin

9-(5-O-acetyl-3-deoxy-β-D-erythro-pentofuranosyl)adenine
137530-37-1

9-(5-O-acetyl-3-deoxy-β-D-erythro-pentofuranosyl)adenine

Conditions
ConditionsYield
With CAL In tetrahydrofuran at 60℃; for 0.5h; Acetylation;85%
With 1-butyl-3-methylimidazolium Tetrafluoroborate at 50℃; for 6h; Sonication; Enzymatic reaction; regioselective reaction;
cordycepin
73-03-0

cordycepin

(2R,3R,5S)-2-(6-amino-9H-purin-9-yl)-5-(chloromethyl)tetrahydrofuran-3-ol
57274-15-4

(2R,3R,5S)-2-(6-amino-9H-purin-9-yl)-5-(chloromethyl)tetrahydrofuran-3-ol

Conditions
ConditionsYield
With thionyl chloride In N,N,N,N,N,N-hexamethylphosphoric triamide for 6h;80%
With pyridine; thionyl chloride In acetonitrile at 0 - 20℃; for 19h;61%
With 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone; thionyl chloride at 0℃; for 7h;
cordycepin
73-03-0

cordycepin

propionyl chloride
79-03-8

propionyl chloride

N-propionyl-cordycepin
77378-04-2

N-propionyl-cordycepin

Conditions
ConditionsYield
With pyridine at 60℃; Inert atmosphere; Reflux;75.5%
cordycepin
73-03-0

cordycepin

mono-4-methoxytrityl chloride
14470-28-1

mono-4-methoxytrityl chloride

9-<5-O-(monomethoxytrityl)-3-deoxy-β-D-erythro-pentofuranosyl>adenine
51763-58-7

9-<5-O-(monomethoxytrityl)-3-deoxy-β-D-erythro-pentofuranosyl>adenine

Conditions
ConditionsYield
With pyridine at 50℃; for 5h;74%
4,4'-dimethoxytrityl chloride
40615-36-9

4,4'-dimethoxytrityl chloride

cordycepin
73-03-0

cordycepin

benzoyl chloride
98-88-4

benzoyl chloride

N-(9-((2R,3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3-hydroxytetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide
84138-86-3

N-(9-((2R,3R,5S)-5-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-3-hydroxytetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide

Conditions
ConditionsYield
Stage #1: 4,4'-dimethoxytrityl chloride; cordycepin With pyridine; N-ethyl-N,N-diisopropylamine In 1,4-dioxane at 20℃; for 3h;
Stage #2: benzoyl chloride In pyridine
69%
cordycepin
73-03-0

cordycepin

4-methoxy-phenyl-sulphonyl chloride
98-68-0

4-methoxy-phenyl-sulphonyl chloride

purine-6-(4-methoxy-benzenesulfonamido)-9-N-(3'-deoxy)ribofuranoside

purine-6-(4-methoxy-benzenesulfonamido)-9-N-(3'-deoxy)ribofuranoside

Conditions
ConditionsYield
Stage #1: cordycepin With sodium hydride In N,N-dimethyl-formamide at 20℃; for 0.5h;
Stage #2: 4-methoxy-phenyl-sulphonyl chloride In N,N-dimethyl-formamide
68.6%
cordycepin
73-03-0

cordycepin

chlorodimethyl(1,1,2-trimethylpropyl)silane
67373-56-2

chlorodimethyl(1,1,2-trimethylpropyl)silane

(2R,3R,5S)-2-(6-Amino-purin-9-yl)-5-[dimethyl-(1,1,2-trimethyl-propyl)-silanyloxymethyl]-tetrahydro-furan-3-ol
153764-71-7

(2R,3R,5S)-2-(6-Amino-purin-9-yl)-5-[dimethyl-(1,1,2-trimethyl-propyl)-silanyloxymethyl]-tetrahydro-furan-3-ol

Conditions
ConditionsYield
With pyridine for 20h; Ambient temperature;68%
cordycepin
73-03-0

cordycepin

n-octanoic acid chloride
111-64-8

n-octanoic acid chloride

3-deoxy-β-D-ribofuranosyl-N6-biotinyladenine
77378-05-3

3-deoxy-β-D-ribofuranosyl-N6-biotinyladenine

Conditions
ConditionsYield
With pyridine at 60℃; Inert atmosphere; Reflux;64.3%

73-03-0Relevant articles and documents

-

Suhadolnik et al.

, p. 948 (1964)

-

A NUCLEOSIDE DERIVATIVE FROM EMERICELLA NIDULANS

Kawahara, Nobuo,Sekita, Setsuko,Satake, Motoyoshi,Udagawa, Shun-Ichi

, p. 1409 - 1410 (1992)

5'-Acetyl-3'-deoxyadenosine, a new nucleoside derivative, has been isolated from Emericella nidulans var. lata, together with 3'-deoxyadenosine (cordycepin). Key Word Index: Emericella nidulans; Ascomycotina; fungus; nucleoside; 5'-acetyl-3'-deoxyadenosine; 3'-deoxyadenosine.

Synthesis method of cordycepin

-

Paragraph 0022; 0023; 0033-0037, (2020/07/13)

The invention discloses a synthetic method for cordycepin. The method comprises the following steps: with adenosine as a starting material, subjecting adenosine and Mattock's bromide to bromination in a reaction solvent of acetonitrile and/or ethyl acetate during implementation of hydroxyl protection so as to obtain two products, i.e., 5'-[2,5,5-trimethyl-1,3-dioxolane-4-one-2-yl]-3'-bromo-3'-deoxy-2'-O-acetyl adenosine and 5'-[2,5,5-trimethyl-1,3-dioxolane-4-one-2-yl]-2'-bromo-2'-deoxy-3'-O-acetyl adenosine; then removing protective groups so as to obtain 3'-bromo-3'-deoxy-adenosine hydrochloride; and subjecting 3'-bromo-3'-deoxy-adenosine hydrochloride to debromination so as to obtain 3'-deoxyadenosine, i.e., cordycepin. The synthetic method provided by the invention is simple to operate, has short reaction steps and does not need purification in the process of reaction; and the purity and each index of the obtained cordycepin product are better than a currently commercially available cordycepin product.

Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation

-

, (2018/11/10)

The disclosed invention is a composition for and a method of seating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

Preparation method of cordycepin

-

Paragraph 0074-0078, (2018/11/03)

The invention discloses a preparation method of cordycepin. The preparation method comprises the following steps: a formula is shown in the description, wherein X is Cl or Br; R1 is one of the following groups: formulas are shown in the description; R2 is one of the following groups: formulas are shown in the description. The preparation method disclosed by the invention takes easy-to-obtain adenosine as a starting raw material and is simple to operate and convenient for purification and industrial large-scale production is easy to realize.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 73-03-0